PEPTOKING
EN

CagriSema delivers 22.7% weight loss in REDEFINE 1, below Novo's 25% expectation

Trial result

Novo Nordisk reported that CagriSema, a once-weekly combination of the amylin analogue cagrilintide 2.4 mg and semaglutide 2.4 mg, produced 22.7% average weight loss at 68 weeks in the phase 3 REDEFINE 1 trial of 3,417 adults with obesity or overweight. Cagrilintide alone gave 11.8%, semaglutide alone 16.1% and placebo 2.3%. The result fell short of the roughly 25% the company had signaled, and Novo shares fell about 20% that day.

Sources

  1. 01CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial(opens the source in a new tab) Novo Nordisk via GlobeNewswire
  2. 02Novo Nordisk shares plunge 20% after disappointing trial results; Lilly jumps(opens the source in a new tab) CNBC

Peptides involved

  1. In clinical trialsCagrilintideLong-acting amylin analog (amylin and calcitonin receptor agonist)37 WADA banned
  2. ApprovedSemaglutideGLP-1 receptor agonist31